Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Cash from Investing Activities (2016 - 2025)

International Stem Cell (ISCO) has disclosed Cash from Investing Activities for 16 consecutive years, with -$3000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 92.5% to -$3000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$43000.0, a 74.85% increase, with the full-year FY2024 number at -$171000.0, down 106.02% from a year prior.
  • Cash from Investing Activities was -$3000.0 for Q3 2025 at International Stem Cell, up from -$32000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$2000.0 in Q1 2021 to a low of -$119000.0 in Q2 2024.
  • A 5-year average of -$20352.9 and a median of -$9000.0 in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 95.12% in 2021, then tumbled 250.0% in 2023.
  • International Stem Cell's Cash from Investing Activities stood at -$18000.0 in 2021, then surged by 83.33% to -$3000.0 in 2022, then changed by 0.0% to -$3000.0 in 2023, then changed by 0.0% to -$3000.0 in 2024, then changed by 0.0% to -$3000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Cash from Investing Activities are -$3000.0 (Q3 2025), -$32000.0 (Q2 2025), and -$5000.0 (Q1 2025).